CDSCO Panel Rejects Troikaa Pharma's High-Strength Paracetamol Injection
Ahmedabad-based pharma firm Troikaa Pharmaceuticals Limited was refused approval by the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) for its Paracetamol Injection 1000 mg/4 ml due to safety concerns.
The decision was made during the committee's 8th meeting on September 17, 2025, at CDSCO headquarters in New Delhi, where the firm provided clarifications on observations from the SEC meeting on June 24, 2025.
No specific quote available.
Author's summary: CDSCO rejects Troikaa Pharma's injection.
More News
- Afreximbank to launch financing window for Africa’s mineral processing projects
- Mayor Johnson’s record-setting $1 billion TIF surplus highlights issues and abuse of Chicago’s Tax Increment Financing districts
- Trump “National Police Force” Built on ICE Partnerships With Local Agencies Like… Wildlife Commissions?
- UN Experts Warn Japan’s School Pamphlets Threaten Religious Minorities
- Sophie Turner, Chris Martin new couple in Tinseltown?
- 'A House Of Dynamite' Ending Explained – Can The U.S. Stop A Nuclear Missile? What Decision Does The President Make? | Trending News Buzz
- The Post-Gaza Rebalancing in the Middle East